COMMUNIQUÉS West-GlobeNewswire

Gala Pharmaceutical to Present at World Cbd Expo
17/01/2019
IRVINE, Calif., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Gala Pharmaceutical, Inc. (OTC: GLPH), a provider of cannabis testing in Southern California, today announced that Gala Pharmaceutical Inc. will be presenting at the [...]
AMAG Pharmaceuticals Completes Acquisition of Perosphere Pharmaceuticals
17/01/2019
Adds Next Generation Small Molecule Anticoagulant Reversal Agent to Development Pipeline to Leverage AMAG’s Expertise in Hematology WALTHAM, Mass., Jan. 17, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: [...]
RedHill Biopharma Announces Fifth U.S. Patent Covering TALICIA® for H. pylori Infection
17/01/2019
Notice of Allowance received and, once granted, the new U.S. patent is expected to be valid until 2034 NDA submission is expected in H1/2019, with eligibility for 6-month priority review; Subject to FDA approval, U.S. [...]
Geron Appoints Vice President, Pharmacovigilance and Drug Safety
17/01/2019
MENLO PARK, Calif., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced the hiring of the first of several key leadership positions as it rebuilds the in-house development team to support [...]
Rafael Pharmaceuticals to Present Plan for Phase 3 Trial (AVENGER 500) of devimistat (CPI-613®) in Combination with Modified FOLFIRINOX as a First Line Treatment for Metastatic Pancreatic Cancer at 2019 Gastrointestinal Cancers Symposium
17/01/2019
Newark, NJ, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that the study plan for a Phase 3 Trial (AVENGER 500) of [...]
Wellness Matrix Group To Initiate State-of-the-Art Wellness Model Program
17/01/2019
LOS ANGELES, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Wellness Matrix Group, Inc. (OTC:WMGR) announces today that it will shortly introduce what it considers the world's most technologically advanced health care models in [...]
Progressive Care Releases Open Letter to Shareholders
17/01/2019
Open Letter to Shareholders Summarizes Recent Milestones MIAMI, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Progressive Care Inc. (OTCQB:RXMD), through its PharmCo subsidiaries, is a South Florida health services organization and [...]
Quotient Limited to Report Fiscal Third Quarter 2019 Financial Results and Host Conference Call
17/01/2019
JERSEY, Channel Islands, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third quarter ended December 31, [...]
Canopy Rivers Appoints Former OMERS Venture Capital Specialist as President
17/01/2019
TORONTO, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Canopy Rivers Inc. (the “ Company ” or “ Canopy Rivers ”) (TSXV: RIV) today announced that Narbe Alexandrian has been appointed as President of the Company, effective [...]
American Postal Workers Union Health Plan Selects Inovalon ONE® Platform
17/01/2019
Partnership Focuses on Leveraging Advanced Analytics and Technologies to Improve Quality and Financial Performance BOWIE, Md. , Jan. 17, 2019 (GLOBE NEWSWIRE) -- Inovalon (Nasdaq: INOV), a leading technology company [...]
Ossur Hf : Q4&FY 2018 Results - Conference call Tuesday 5 February at 9:00 CET
17/01/2019
Announcement no. 03/2018 17 January 2019 Conference call on Tuesday 5 February at 9:00 CET / 8:00 GMT / 3:00 EDT Össur will publish its financial results for Q4&FY 2018 prior to market opening on Tuesday 5 February [...]
ProMIS Neurosciences to Participate in NobleCon15 and CanTech Investment Conferences
17/01/2019
Company to showcase its innovative Alzheimer’s, Parkinson’s and ALS programs TORONTO and CAMBRIDGE, Mass., Jan. 17, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company [...]
Moleculin Announces Dr. James L. Abbruzzese, Chief of Medical Oncology Division at Duke University, Joins Science Advisory Board
17/01/2019
Dr. Abbruzzese to add significant pancreatic cancer expertise to advance drug development HOUSTON, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical [...]
Lexicon Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Sotagliflozin New Drug Application for the Treatment of Type 1 Diabetes
17/01/2019
THE WOODLANDS, Texas, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that NASDAQ has halted trading of the company’s common stock. The U.S. Food and Drug Administration’s [...]
First Patient Dosed in Phase 1 Clinical Trial Evaluating Neoepitopes Formulated in IMV’s DPX Delivery Platform in Ovarian Cancer Patients
17/01/2019
DARTMOUTH, Nova Scotia, Jan. 17, 2019 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that the first patient has been treated in the Phase 1 trial [...]
HEXO to begin trading on the NYSE American
17/01/2019
GATINEAU, Quebec, Jan. 17, 2019 (GLOBE NEWSWIRE) -- HEXO Corp. (“HEXO” or the “Company”) (TSX: HEXO ) is pleased to announce that its common shares have been approved for listing on the NYSE American LLC ("NYSE American [...]
Début des négociations des actions d’HEXO au NYSE American
17/01/2019
GATINEAU, Québec, 17 janv. 2019 (GLOBE NEWSWIRE) -- HEXO Corp. (« HEXO » ou la « Société ») (TSX: HEXO ) a le plaisir d’annoncer que l’inscription de ses actions ordinaires au NYSE American LLC (« NYSE American ») a été [...]
AVROBIO, Inc. Announces Analyst and Investor Event and Upcoming Clinical Data Presentations at WORLDSymposium 2019
17/01/2019
Analyst and Investor Event to be Webcast on Wednesday, February 6, 2019 at 6:30 p.m. ET CAMBRIDGE, Mass., Jan. 17, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc . (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene [...]
Zafgen Announces Positive Results for Second Cohort of Phase 2 Clinical Trial of ZGN-1061
17/01/2019
Data for the 1.8 mg dose demonstrated meaningfully greater efficacy than the 0.9 mg dose Cohort 2 data showed statistically and clinically significant 1.1% reduction of A1C at the 1.8 mg dose relative to placebo [...]

Pages